The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ACET | -38.13% | -92.83% | -40.97% | -94% |
| S&P | +14.84% | +96.04% | +14.41% | +99% |
Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.
These companies' share prices could rise in the short term, but their long-term opportunities are even better.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$1.60M | 0.1% |
| Market Cap | $50.45M | -49.3% |
| Market Cap / Employee | $0.33M | 0.0% |
| Employees | 152 | 6.3% |
| Net Income | -$31.22M | -4.4% |
| EBITDA | -$30.79M | 1.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $34.72M | -84.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $12.41M | -21.0% |
| Short Term Debt | $2.95M | -13.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -54.95% | -4.7% |
| Return On Invested Capital | -40.82% | -1.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$26.68M | -12.5% |
| Operating Free Cash Flow | -$26.63M | -13.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.50 | 0.37 | 0.33 | 0.31 | -18.66% |
| Price to Tangible Book Value | 0.50 | 0.37 | 0.33 | 0.31 | -18.66% |
| Enterprise Value to EBITDA | 1.68 | 2.46 | 2.32 | 1.76 | -42.44% |
| Return on Equity | -58.0% | -65.7% | -55.8% | -64.4% | 11.20% |
| Total Debt | $18.20M | $17.23M | $16.25M | $15.36M | -19.73% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
